A Randomized, Double-Blind, Triple-Dummy, Single-Dose, Four-Way Crossover Study to Determine the Relative Bioavailability, Pharmacodynamic Effects, and Safety of Equivalent Doses of Whole and Crushed ALO-01 Versus Morphine IR in Opioid Experienced, Non-Dependent Subjects.

Trial Profile

A Randomized, Double-Blind, Triple-Dummy, Single-Dose, Four-Way Crossover Study to Determine the Relative Bioavailability, Pharmacodynamic Effects, and Safety of Equivalent Doses of Whole and Crushed ALO-01 Versus Morphine IR in Opioid Experienced, Non-Dependent Subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2013

At a glance

  • Drugs Morphine/naltrexone (Primary) ; Morphine
  • Indications Pain
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Alpharma
  • Most Recent Events

    • 18 Mar 2009 Results presented at the 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, 2009.
    • 29 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top